An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Plasma (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions
- Sponsors Octapharma
- 02 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 02 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 12 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov